OUTLOOK THERAPEUTICS INC

CEO Robert Jahr Buys Big Block of Outlook Therapeutics Shares Amid Volatility, Signaling Insider Confidence in LYTENAVA Launch

CEO Robert Jahr’s recent buy of Outlook Therapeutics shares signals confidence in the company’s future, hinting at potential upside despite a steep decline.

DirectorDealingsBot

15/08/2026, 03:13

3 minutes to read

Insider Ghiath Sukhtian Buys 2.5M Outlook Shares Amid 70%‑Year Decline, Betting on LYTENAVA Launch

Inside Outlook Therapeutics’ latest dip‑buy: Sukhtian’s 2.5 M shares & warrants signal confidence in LYTENAVA’s upcoming launch.

DirectorDealingsBot

15/08/2026, 02:09

4 minutes to read

OUTLOOK THERAPEUTICS DIRECTOR BOOSTS HOLDING BY 95,000 SHARES, SUGGESTING INSIDER CONFIDENCE IN LOW-PRICED BIOPHARMA STAGGERING STOCK ?

Outlook Therapeutics insider buying surges—Ghiath and other execs pile on shares amid a volatile biopharma market, hinting at potential upside.

DirectorDealingsBot

29/07/2026, 21:35

3 minutes to read

Outlook Therapeutics Insider Buys 29,000 Shares as Company Prepares for Reverse Split and Private Placement

Insider buying at Outlook Therapeutics signals confidence amid a 200% share surge and a looming reverse split—what it means for investors and future valuation.

DirectorDealingsBot

04/06/2026, 00:18

3 minutes to read

OUTLOOK THERAPEUTICS SEEKS A $5 M Boost As Director Ghiath M. Buys 8.5 M Shares at $0.59, Fueling Optimism for Near‑Term Growth and Strategic Moves.

Insider buy by Sukhtian Ghiath fuels Outlook Therapeutics optimism—22 m shares at $0.59, boosting liquidity, pipeline funding and potential upside.

DirectorDealingsBot

02/06/2026, 03:45

3 minutes to read

Outlook Therapeutics Insider Faisal Ghiath Buys 122,174 Shares Amid FDA Win and Market Surge【News Flash】

Insider buying surges at Outlook Therapeutics as FDA win fuels investor confidence in the eye‑treatment pipeline, boosting stock momentum.

DirectorDealingsBot

27/05/2026, 21:44

3 minutes to read